STM 434 + liposomal doxorubicin

STM 434 + liposomal doxorubicin is an investigational drug combination being studied for the treatment of ovarian cancer and other advanced solid tumors. STM 434 is a soluble receptor ligand trap targeting **activin A**, part of the TGF-β family, and acts by inhibiting activin A signaling implicated in tumor growth, metabolism, and cancer cachexia. Liposomal doxorubicin is a chemotherapy agent encapsulated in liposomes to reduce toxicity and enhance delivery; it intercalates DNA and inhibits topoisomerase II, leading to apoptosis of cancer cells. The combination is designed to maximize anti-tumor efficacy and mitigate the cachexia often seen in advanced cancers. STM 434 was developed and investigated by Santa Maria Biotherapeutics as part of a phase I open-label clinical trial in advanced solid tumors, including ovarian, fallopian tube, and endometrial cancers. Primary endpoints included safety, pharmacokinetics, and maximum tolerated dose. While STM 434 showed metabolic effects relevant to cachexia, no direct anti-tumor efficacy was observed, and further development was discontinued[1][2][3][4][6][9].

Other names

STM-434 and liposomal doxorubicinSTM434 and liposomal doxorubicinSTM 434 and liposomal doxorubicinSTM 434 plus liposomal doxorubicinSTM434 plus liposomal doxorubicinSTM-434 plus liposomal doxorubicin